MSLE on Nasdaq

Satellos Bioscience Inc.

Satellos Bioscience Inc. is a pharmaceutical preparations company based in Toronto, listed on Nasdaq (MSLE).1

Price unavailable

Last updated Oct 20, 2026.

Overview

-$24.9MNet income, fiscal 20252

Compare with another stock.

  • TickerMSLE on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersZ41
  • Incorporated inCanada (Federal Level)3
  • Business address15 Allstate Parkway, Suite 600, Markham, L3R 5B43
  • Filer category, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-89.5%Return on equity2
-$23.6MFree cash flow2

Financial statements

Operating income2-$26.5M in 2025+30% since 2024
-$30.0M-$20.0M-$10.0M02024: -$20.4M-$20.4M20242025: -$26.5M-$26.5M2025+30%
Net income2-$24.9M in 2025+21% since 2024
-$30.0M-$20.0M-$10.0M02024: -$20.6M-$20.6M20242025: -$24.9M-$24.9M2025+21%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-12-312024-12-31
"Research and development (""R&D"")"18.4M CAD19.6M CAD
"General and administrative (""G&A"")"8.0M CAD8.2M CAD
TOTAL OPERATING EXPENSES:-26.5M CAD-27.8M CAD
Finance income1.4M CAD1.4M CAD
Impairment of intangible asset-4.0M CAD
Loss on derivative financial instruments-2.0K CAD
Foreign exchange gain398.0K CAD2.3M CAD
NET LOSS BEFORE INCOME TAXES-$24.7M-$20.6M
Income tax expense-$172.0K
NET LOSS FOR THE YEAR-24.9M CAD-28.1M CAD
Foreign currency translation adjustment17.0K CAD-202.0K CAD
TOTAL COMPREHENSIVE LOSS-24.9M CAD-28.3M CAD
Basic loss per Common Share (in dollars per share)-$1.70-$2.16
Diluted loss per Common Share (in dollars per share)-$1.70-$2.16
Basic loss per Pre-Funded Warrant (in dollars per share)$0.00$0.00
Diluted loss per Pre-Funded Warrant (in dollars per share)$0.00$0.00
Weighted average number of Common Shares, basic (in shares)14.6M shares9.6M shares
Weighted average number of Common Shares, diluted (in shares)14.6M shares9.6M shares

Compare Satellos Bioscience Inc. with another company

Corporate structure

Satellos Bioscience Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Satellos Bioscience Inc.

  • Brian Matthew Bloom Filed SCHEDULE 13G on Satellos Bioscience Inc., latest May 15, 2026
  • Qiming U.S. Healthcare Fund III, L.P. Filed SCHEDULE 13G on Satellos Bioscience Inc., latest May 12, 2026
  • Satellos Bioscience Inc. Z4

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Satellos Bioscience Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$5.0K2 Dec 31, 2025$4.0K2 Dec 31, 2024+25.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$9.8M2 Dec 31, 2025$40.1M2 Dec 31, 2024−75.5%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerCourtney D. Wells named Jan 3, 20254
  • Executive OfficerElizabeth Williams named Jan 3, 20254
  • Executive Officer, Director, PromoterFrank Gleeson named Sep 27, 2022 to Jan 3, 20254
  • Executive OfficerMichael Robert Cross named Jan 3, 20254
  • Executive OfficerMichael Rudnicki named Sep 27, 2022 to Jan 3, 20254
  • Executive OfficerPhilip D. Lambert named May 25, 2023 to Jan 3, 20254
  • Executive OfficerJ. Robert Hall named Sep 27, 2022 to May 25, 20235
  • Executive OfficerWarren Whitehead named Sep 27, 2022 to May 25, 20235
  • DirectorAdam Mostafa named Sep 27, 2022 to Jan 3, 20254
  • DirectorBill Jarosz named Sep 27, 2022 to Jan 3, 20254
  • DirectorBrian Bloom named Sep 27, 2022 to Jan 3, 20254
  • DirectorFranklin D. Berger named Jan 3, 20254
  • DirectorGeoff MacKay named Sep 27, 2022 to Jan 3, 20254
  • DirectorRima Al-awar named Sep 27, 2022 to Jan 3, 20254
  • DirectorStephanie D. Brown named Jan 3, 20254
  • DirectorWilliam McVicar named Sep 27, 2022 to Jan 3, 20254

Former names

  • ICO THERAPEUTICS INCDec 17, 2007 to Sep 10, 20193

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/20266

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

42 filings to the SEC since October 2021: 1 annual reports, 2 large holders, 3 private raises, 36 other. The latest 20:

  1. Oct 5, 20266-K EDGAR
  2. Sep 30, 20266-K EDGAR
  3. Sep 24, 20266-K EDGAR
  4. Sep 15, 20266-K EDGAR
  5. Sep 9, 20266-K EDGAR
  6. Sep 1, 20266-K EDGAR
  7. Aug 14, 20266-K EDGAR
  8. Aug 14, 2026SUPPL EDGAR
  9. Aug 13, 20266-K EDGAR
  10. Aug 11, 2026F-X EDGAR
  11. Aug 11, 2026F-10 EDGAR
  12. Jul 8, 20266-K EDGAR
  13. Jun 29, 20266-K EDGAR
  14. Jun 25, 20266-K EDGAR
  15. Jun 18, 20266-K EDGAR
  16. Jun 17, 20266-K EDGAR
  17. May 27, 20266-K EDGAR
  18. May 20, 20266-K EDGAR
  19. May 15, 2026SCHEDULE 13G EDGAR
  20. May 15, 20266-K EDGAR

The 42 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 20, 2024Raised $25 million in a private offering of equity Form D: 13 investors so far Form D
  2. May 10, 2023Raised $33.3 million in a private offering of equity Form D: 16 investors so far Form D
  3. Sep 13, 2022Raised $99,161 in a private offering of equity Form D: $2.1 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 26. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Franklin Resources Inc938,666$7.2M0.0%No change
Siren, L.L.C.892,074$6.9M0.1%No change
Vivo Capital, LLC813,666$6.3M0.6%No change
Point72 Asset Management, L.P.682,700$5.3M0.0%−8,078
Sphera Funds Management Ltd.652,590$5.1M0.7%+163,383
Woodline Partners LP500,432$3.9M0.0%No change
Stonepine Capital Management, LLC491,624$3.7M2.8%+391,624
Montanova Capital, LLC475,000$3.7M0.1%No change
Avidity Partners Management LP387,769$3.0M0.5%−387,769
Saturn V Capital Management LP350,000$2.7M0.4%No change
Soleus Capital Management, L.P.314,359$2.4M0.1%−100,000
683 Capital Management, LLC230,833$1.8M0.2%No change
ADAR1 Capital Management, LLC222,555$1.7M0.1%No change
AWM Investment Company, Inc.180,000$1.4M0.1%New
Millennium Management LLC152,768$1.2M0.0%−145,665
Adage Capital Partners Gp, L.l.c.150,000$1.2M0.0%−230,354
Empery Asset Management, LP107,100$832.7K1.0%−123,000
Citadel Advisors LLC67,738$526.7K0.0%+25,246
Morgan Stanley25,732$200.1K0.0%+4,549
China Universal Asset Management Co., Ltd.20,000$155.5K0.0%+13,600
Royal Bank Of Canada15,863$124.0K0.0%−382
Geode Capital Management, LLC11,907$92.6K0.0%No change
UBS Group AG781$6.1K0.0%+753
Jpmorgan Chase & Co315$2.5K0.0%New
Federation des caisses Desjardins du Quebec19$1430.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Satellos Bioscience Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSatellos Bioscience Inc.1
  • CIK0001421642
  • Employer ID (EIN)00-00000009
  • Filer status<br>emerging growth company an emerging growth company1
  • Incorporated inCanada9
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address15 Allstate Parkway, Suite 600, Markham, L3R 5B4, Ontario, Canada1
  • Phone647-660-17801
  • Shares outstanding15,458,903 shares as of Dec 31, 20259
  • AuditorPricewaterhouseCoopers LLP, Toronto, Canada PCAOB ID 271; no auditor attestation of internal control over financial reporting9
  • On EDGAR sinceDec 17, 20071
  • Filings51 in all: 6-K (27), D (8), D/A (2), F-10 (2), F-X (2), REGDEX (2), SCHEDULE 13G (2), SUPPL (2)1
    All 12 form types

    40-F (1), 8-A12B (1), CERT (1), S-8 (1)

  • Latest filingsAnnual report (40-F) Mar 27, 2026

Securities registered for trading

ClassSymbolExchange
Common Shares, no par valueMSLEThe Nasdaq Stock Market LLC

From the cover page of the 40-F filed Mar 27, 2026 (Section 12(b) of the Exchange Act).9

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9